Compared with cell lines not bearing mutations in BRAF and PIK3CA, colorectal cancer cell lines with BRAF mutations with or without PIK3CA mutations show heterogeneous up-regulation in the mRNA expression of genes that are targets of the BRAF/MEK/ERK pathway. This evidence concerns the gene BRAF and colorectal cancer.